Caris Life Sciences (NASDAQ: CAI) announced the launch of Caris ChromoSeq, a whole genome and whole transcriptome sequencing assay for myeloid malignancies. The test is designed for use in acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms, as well as patients with suspected myeloid malignancies characterized by unexplained cytopenia persisting for more than four months.

The assay delivers approximately 250x read depth across the genome with 40 million transcriptome reads from bone marrow aspirate or peripheral blood collection. The company states the test can replace multiple test protocols in the myeloid diagnostic workflow, with results provided in a seven-day turnaround time.

"The Caris ChromoSeq launch provides an unprecedented amount of genomic and transcriptomic data per patient, enabling a complete diagnostic evaluation in a single test," said Matthew Oberley, MD, PhD, Senior Vice President, Chief Clinical Officer and Pathologist-in-Chief at Caris.

Myeloid malignancies typically require multiple tests to identify clinically relevant mutations, structural variants and chromosomal abnormalities. The company indicates its test addresses this fragmented approach that can delay treatment decisions.

Irving, Texas-based Caris Life Sciences operates as a precision medicine company focused on molecular profiling technologies. The company has offices in Phoenix, New York, Cambridge, Tokyo, and Basel, providing services in the United States and international markets.